Expertise in
15
conditions

Dr. Andrew B. Lassman

Neurology
Trustees Of Columbia University In The City Of New York
51 W 51st St, 
New York, NY 
Offers Telehealth
Expertise in
15
conditions
Trustees Of Columbia University In The City Of New York
51 W 51st St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Lassman is a Neurologist in New York, New York. Dr. Lassman is highly rated in 15 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri.

His clinical research consists of co-authoring 122 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
51 W 51st St, New York, NY 10019
Other Locations
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
710 W 168th St, New York, NY 10032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma
A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma
Enrollment Status: Terminated
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drug: ONC201
Study Phase: Phase 2
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2024
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Pilot Trial of Temsirolimus and Perifosine in Recurrent/Progressive Malignant Gliomas
Pilot Trial of Temsirolimus and Perifosine in Recurrent/Progressive Malignant Gliomas
Enrollment Status: Completed
Publish Date: May 25, 2023
Intervention Type: Procedure, Drug
Study Drugs: Perifosine, Temsirolimus
Study Phase: Phase 1
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
Enrollment Status: Terminated
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
Enrollment Status: Completed
Publish Date: September 17, 2019
Intervention Type: Procedure, Biological
Study Phase: Phase 2
View 7 Less Clinical Trials

121 Total Publications

Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 08, 2025
Similar Doctors
Expertise in
32
conditions
Dr. Orrin Devinsky
Neurology | General Surgery
Expertise in
32
conditions
Dr. Orrin Devinsky
Neurology | General Surgery

New York University

223 E 34th St, 
New York, NY 
 (1.1 miles away)
646-558-0800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Orrin Devinsky is a Neurologist and a General Surgeon in New York, New York. Dr. Devinsky is highly rated in 32 conditions, according to our data. His top areas of expertise are Myoclonic Epilepsy, Dravet Syndrome, Seizures, Epilepsy, and Deep Brain Stimulation.

Expertise in
14
conditions
Dr. Horacio C. Kaufmann
Neurology
Expertise in
14
conditions
Dr. Horacio C. Kaufmann
Neurology

Dysautonomia Center Llp

530 1st Ave, Suite 9q, 
New York, NY 
 (1.4 miles away)
212-263-7225
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Horacio Kaufmann is a Neurologist in New York, New York. Dr. Kaufmann is highly rated in 14 conditions, according to our data. His top areas of expertise are Familial Dysautonomia, Hereditary Sensory and Autonomic Neuropathy Type 2, Hajdu-Cheney Syndrome, and Orthostatic Hypotension.

Expertise in
21
conditions
Dr. Thomas J. Kaley
Neurology
Expertise in
21
conditions
Dr. Thomas J. Kaley
Neurology

Memorial Neurology Group

1275 York Ave, 
New York, NY 
 (1.3 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Kaley is a Neurologist in New York, New York. Dr. Kaley is highly rated in 21 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioblastoma, Meningioma, and Glioma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lassman's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile